{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:25:54Z","timestamp":1780086354724,"version":"3.54.0"},"reference-count":25,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>In the current work, a simple, economical, accurate, and precise HPLC method with UV detection was developed to quantify Favipiravir (FVIR) in spiked human plasma using acyclovir (ACVR) as an internal standard in the COVID-19 pandemic time. Both FVIR and ACVR were well separated and resolved on the C18 column using the mobile phase blend of methanol:acetonitrile:20 mM phosphate buffer (pH 3.1) in an isocratic mode flow rate of 1 mL\/min with a proportion of 30:10:60 %, v\/v\/v. The detector wavelength was set at 242 nm. Maximum recovery of FVIR and ACVR from plasma was obtained with dichloromethane (DCM) as extracting solvent. The calibration curve was found to be linear in the range of 3.1\u201360.0 \u00b5g\/mL with regression coefficient (r2) = 0.9976. However, with acceptable r2, the calibration data\u2019s heteroscedasticity was observed, which was further reduced using weighted linear regression with weighting factor 1\/x. Finally, the method was validated concerning sensitivity, accuracy (Inter and Intraday\u2019s % RE and RSD were 0.28, 0.65 and 1.00, 0.12 respectively), precision, recovery (89.99%, 89.09%, and 90.81% for LQC, MQC, and HQC, respectively), stability (% RSD for 30-day were 3.04 and 1.71 for LQC and HQC, respectively at \u221220 \u00b0C), and carry-over US-FDA guidance for Bioanalytical Method Validation for researchers in the COVID-19 pandemic crisis. Furthermore, there was no significant difference for selectivity when evaluated at LLOQ concentration of 3 \u00b5g\/mL of FVIR and relative to the blank.<\/jats:p>","DOI":"10.3390\/molecules26133789","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T22:10:59Z","timestamp":1624399859000},"page":"3789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4263-0134","authenticated-orcid":false,"given":"Mohammad","family":"Hailat","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Al-Ani","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Al-Ahliyya Amman University, Amman 19328, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-8206","authenticated-orcid":false,"given":"Mohammed","family":"Hamad","sequence":"additional","affiliation":[{"name":"College of Science and Health Professions, King Saud Bin Abdulaziz University for Health Sciences, Jeddah 21423, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Zakareia","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Medical Sciences, University of Petra, Amman 11196, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2432-9356","authenticated-orcid":false,"given":"Wael","family":"Abu Dayyih","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Medical Sciences, University of Petra, Amman 11196, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wiersinga, W.J., Rhodes, A., Cheng, A.C., Peacock, S.J., and Prescott, H.C. (2020). Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA J. Am. Med Assoc., 782\u2013793.","DOI":"10.1001\/jama.2020.12839"},{"key":"ref_2","unstructured":"Bulduk, \u0130. (2020). HPLC-UV Method for Quantification of Favipiravir in Pharmaceutical Formulations. Acta Chromatogr., 1."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Furuta, Y., Gowen, B.B., Takahashi, K., Shiraki, K., Smee, D.F., and Barnard, D.L. (2013). Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor. Antivir. Res., 446\u2013454.","DOI":"10.1016\/j.antiviral.2013.09.015"},{"key":"ref_4","unstructured":"Bosaeed, M. (2021, April 07). FAvipiravir and HydroxyChloroquine Combination Therapy\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04392973?term=NCT04392973&draw=2&rank=1."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Saber-Ayad, M., Saleh, M.A., and Abu-Gharbieh, E. (2020). The Rationale for Potential Pharmacotherapy of Covid-19. Pharmaceuticals, 13.","DOI":"10.3390\/ph13050096"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sohrabi, C., Alsafi, Z., O\u2019Neill, N., Khan, M., Kerwan, A., Al-Jabir, A., Iosifidis, C., and Agha, R. (2020). World Health Organization Declares Global Emergency: A Review of the 2019 Novel Coronavirus (COVID-19). Int. J. Surg., 71\u201376.","DOI":"10.1016\/j.ijsu.2020.02.034"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhu, R.F., Gao, Y.L., Robert, S.H., Gao, J.P., Yang, S.G., and Zhu, C.T. (2020). Systematic Review of the Registered Clinical Trials of Coronavirus Disease 2019 (COVID-19). MedRxiv.","DOI":"10.1101\/2020.03.01.20029611"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1248\/cpb.c18-00725","article-title":"Quality Assessment of Medicinal Product and Dietary Supplements Containing Vitex agnus-castus by HPLC Fingerprint and Quantitative Analyses","volume":"67","author":"Sogame","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129902","DOI":"10.1016\/j.molstruc.2021.129902","article-title":"Evidence of Human Metabolites of Omeprazole and Its Structure Elucidation by Using HPLC-MS","volume":"1230","author":"Hailat","year":"2021","journal-title":"J. Mol. Struct."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wang, C., Dong, H., Liu, H., Sun, Z., Yuan, A., Wu, J., and Hu, Y. (2019). Using HPLC to analyze (S)-oxiracetam and four related substances in the bulk drug of (S)-oxiracetam. J. Pharm. Biomed. Anal.","DOI":"10.1016\/j.jpba.2019.113072"},{"key":"ref_11","unstructured":"Guangling, F., Wenjuan, D., Yuxiao, D., Renyong, Z., Yanyan, G., Chonggang, D., and Jinrui, S. (2016). A Kind of Favipiravir Has the HPLC Assay Method of Related Substance. (CN104914185B)."},{"key":"ref_12","unstructured":"Guangling, F., Wenjuan, D., Yuxiao, D., Renyong, Z., Yanyan, G., Chonggang, D., and Jinrui, S. (2016). HPLC Method for Measuring Related Substances in Favipiravir. (CN104914185A), Patent."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.2147\/IDR.S287934","article-title":"Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database","volume":"13","author":"Kaur","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Acquavia, M.A., Foti, L., Pascale, R., Nicol\u00f2, A., Brancaleone, V., Cataldi, T.R.I., Martelli, G., Scrano, L., and Bianco, G. (2021). Detection and Quantification of Covid-19 Antiviral Drugs in Biological Fluids and Tissues. Talanta, 121862.","DOI":"10.1016\/j.talanta.2020.121862"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"114057","DOI":"10.1016\/j.jpba.2021.114057","article-title":"A Novel LC-MS\/MS Method for Determination of the Potential Antiviral Candidate Favipiravir for the Emergency Treatment of SARS-CoV-2 Virus in Human Plasma: Application to a Bioequivalence Study in Egyptian Human Volunteers","volume":"199","author":"Morsy","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40543-018-0160-2","article-title":"An Approach to Select Linear Regression Model in Bioanalytical Method Validation","volume":"10","author":"Sonawane","year":"2019","journal-title":"J. Anal. Sci. Technol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Cho, S.J., Vinter, S., and Garofolo, F. (2019). Crucial Importance of Evaluating Internal Standards (IS) Response and Troubleshooting in Effective LCMS Method Development, Validation and Sample Analysis. Bioanalysis, 1645\u20131647.","DOI":"10.4155\/bio-2019-0245"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nguyen, T.H.T., Guedj, J., Anglaret, X., Laou\u00e9nan, C., Madelain, V., Taburet, A.M., Baize, S., Sissoko, D., Pastorino, B., and Rodallec, A. (2017). Favipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower than Targeted. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005389"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1570-0232(02)00244-1","article-title":"Linear Regression for Calibration Lines Revisited: Weighting Schemes for Bioanalytical Methods","volume":"774","author":"Almeida","year":"2002","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_20","unstructured":"US-FDA (2018). Bioanalytical Method Validation: Guidance for Industry, FDA."},{"key":"ref_21","first-page":"181","article-title":"A Validated High Performance Liquid Chromatographic Method for the Quantification of Favipiravir by PDA Detector","volume":"11","author":"Nadendla","year":"2021","journal-title":"Int. J. Pharma Bio Sci."},{"key":"ref_22","unstructured":"EMA Committee for Medicinal Products for Human Use (CHMP) (2017, April 18). Guideline on Bioanalytical Method Validation. Available online: http:\/\/www.Ema.Europa.Eu\/Docs\/En_GB\/Document_library\/Scientific_guideline\/2011\/08\/WC500109686."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/infdis\/jiz078","article-title":"Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients with Ebola Virus Disease, Guinea, 2015\u2014A Retrospective Observational Study","volume":"220","author":"Kerber","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(82)90055-9","article-title":"Mechanism of Action and Selectivity of Acyclovir","volume":"73","author":"Elion","year":"1982","journal-title":"Am. J. Med."},{"key":"ref_25","unstructured":"RDIF and ChemRar Launch Final Stage of Favipiravir Clinical Trial (2021, April 07). RDIF and ChemRar Launch Final Stage of Favipiravir Clinical Trial. Available online: https:\/\/www.prnewswire.com\/ae\/news-releases\/rdif-and-chemrar-launch-https:\/\/www.prnewswire.com\/ae\/news-releases\/rdif-and-chemrar-launch-final-stage-of-favipiravir-clinical-trial-301064181.html."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/13\/3789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:20:54Z","timestamp":1760163654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/13\/3789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":25,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["molecules26133789"],"URL":"https:\/\/doi.org\/10.3390\/molecules26133789","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}